[Market Focus] SynthecaBio Surges 28% on Transition of AI Drug Development Infrastructure to Google Cloud
SynthecaBio is showing strong performance in early trading.
As of 9:05 a.m. on November 5, SynthecaBio was trading at 5,440 won, up 28.30% (1,200 won) from the previous day.
The surge in investor sentiment is believed to have been influenced by news that the company has transitioned its existing Amazon Web Services (AWS) EKS infrastructure to a Google Cloud Kubernetes Engine (GKE)-based environment. Google Kubernetes Engine is Google Cloud's fully managed Kubernetes service, which helps deploy complex artificial intelligence (AI) applications quickly and consistently through container-based standardization.
Hot Picks Today
"I Might End Up Paying My Entire Salary Just for Interest"... Annual Per-Person Interest Could Reach 6.73 Million Won, 'Yeongkeul-jok' Lament
- "Will I Really Be Left Out If I Don't Use It?"... The App Used by 23 Million Koreans Monthly, Is Naver Feeling the Pressure?
- Jensen Huang: "SK hynix ADR Is Incredibly Successful"
- "We Will No Longer Teach English"...Chinese University Launches Bold AI-Era Experiment
- "Die from Heat or Starve": Amid Unprecedented Heatwave and Delivery Ban, Italian Riders Go on Strike
SynthecaBio is a technology company that supports the discovery and optimization of new drug candidates using artificial intelligence (AI). The company explained that, through this infrastructure transition, it has successfully established a hybrid cloud environment that integrates its own AI Bio Supercomputing (ABS) Center with Google Cloud's GPU and GKE environment.
![[Market Focus] SynthecaBio Surges 28% on Transition of AI Drug Development Infrastructure to Google Cloud](http://www.asiae.co.kr/news/img_view.htm?img=2025110409131793207_1762215197.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
